UK-based specials manufacturer Quantum Pharmaceutical has appointed Andrew Matthews as operations director to maintain high performance standards and develop the business.
Matthews has more than 12 years’ experience in the pharmaceutical and healthcare industries. He has specialist knowledge in product areas for sterile and non-sterile medicines.
Matthews’ experience in quality driven operations management for unlicensed and licensed medicines will assist Quantum Pharmaceutical in its aim of strengthening links with hospitals, care home and home care pharmaceutical providers, as the company broadens its core customer base.
‘Andrew had an excellent CV and great track record as head of manufacturing ‘Specials’ with his former employer, domiciliary care organisation Healthcare At Home,’ said Andy Scaife, md of Quantum Pharmaceutical.
‘With knowledge of this niche sector of the pharmaceutical industry, Andrew is an excellent fit for Quantum but, most importantly, he brings a new skills set which will be of great benefit as we look to exploit new market opportunities.
Quantum Pharmaceutical appoints operations director
Andrew Matthews brings a new set of skills to the company
You may also like
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model